Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024. The company's management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the financial results and provide company updates.
Investors and interested parties can access the conference call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start time. A live audio webcast of the call, along with accompanying slides, will be available on the company's website under the 'Events & Presentations' section. An archived version of the webcast will be accessible approximately two hours after the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale focalizzata su nuove terapie contro il cancro, ha annunciato che riporterà i suoi risultati finanziari del secondo trimestre 2024 martedì 6 agosto 2024. Il team di gestione dell'azienda ospiterà una conferenza telefonica e una trasmissione audio in diretta alle 8:00 a.m. ET lo stesso giorno per discutere i risultati finanziari e fornire aggiornamenti sull'azienda.
Investitori e parti interessate possono accedere alla conferenza telefonica componendo il numero (800) 836-8184 (locale) o (646) 357-8785 (internazionale) almeno 10 minuti prima dell'orario di inizio. Una trasmissione audio in diretta della chiamata, insieme alle diapositive correlate, sarà disponibile sul sito web dell'azienda nella sezione 'Eventi e Presentazioni'. Una versione archiviata della trasmissione sarà accessibile circa due ore dopo l'evento.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), una compañía farmacéutica en etapa comercial centrada en nuevas terapias contra el cáncer, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024. El equipo de gestión de la compañía llevará a cabo una conferencia telefónica y una transmisión de audio en directo a las 8:00 a.m. ET el mismo día para discutir los resultados financieros y proporcionar actualizaciones sobre la empresa.
Los inversionistas y partes interesadas pueden acceder a la conferencia telefónica marcando el (800) 836-8184 (local) o el (646) 357-8785 (internacional) al menos 10 minutos antes de la hora de inicio. Una transmisión de audio en vivo de la llamada, junto con las diapositivas correspondientes, estará disponible en el sitio web de la compañía en la sección 'Eventos y Presentaciones'. Una versión archivada de la transmisión estará accesible aproximadamente dos horas después del evento.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), 혁신적인 암 치료에 집중하는 상업 단계의 제약 회사는 2024년 8월 6일 화요일에 2024년 2분기 재무 결과를 발표할 것이라고 발표했습니다. 회사의 경영팀은 같은 날 오전 8시 ET에 재무 결과를 논의하고 회사 업데이트를 제공하기 위해 전화 회의와 오디오 웹캐스트를 주최할 것입니다.
투자자 및 관심 있는 모든 분들은 시작 시간 최소 10분 전에 (800) 836-8184 (국내) 또는 (646) 357-8785 (국제)로 전화하여 회의에 참석할 수 있습니다. 전화 회의의 실시간 오디오 웹캐스트는 회사 웹사이트의 '이벤트 및 발표' 섹션에서 관련 슬라이드와 함께 제공됩니다. 사건 후 약 두 시간 후에 아카이브된 버전의 웹캐스트를 접근할 수 있습니다.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), une société pharmaceutique en phase commerciale spécialisée dans les nouvelles thérapies contre le cancer, a annoncé qu'elle présentera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août 2024. L'équipe de direction de la société animera une conférence téléphonique et un webinaire audio à 8h00 ET le même jour pour discuter des résultats financiers et fournir des mises à jour sur l'entreprise.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en composant le (800) 836-8184 (local) ou le (646) 357-8785 (international) au moins 10 minutes avant le début. Un webinaire audio en direct de l'appel, ainsi que les diapositives correspondantes, sera disponible sur le site Web de l'entreprise dans la section 'Événements et Présentations'. Une version archivée du webinaire sera accessible environ deux heures après l'événement.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), ein Unternehmen der kommerziellen Phase, das sich auf neuartige Krebstherapien konzentriert, hat angekündigt, dass es am Dienstag, den 6. August 2024, seine Finanzergebnisse für das zweite Quartal 2024 melden wird. Das Managementteam des Unternehmens wird am gleichen Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Audio-Webcast abhalten, um die Finanzergebnisse zu besprechen und Unternehmensupdates bereitzustellen.
Investoren und interessierte Parteien können die Telefonkonferenz unter der Nummer (800) 836-8184 (lokal) oder (646) 357-8785 (international) mindestens 10 Minuten vor Beginn anrufen. Ein Live-Audio-Webcast des Anrufs sowie begleitende Folien werden auf der Website des Unternehmens im Abschnitt 'Veranstaltungen & Präsentationen' verfügbar sein. Eine archivierte Version des Webcasts wird ungefähr zwei Stunden nach der Veranstaltung zugänglich sein.
- None.
- None.
-- Conference Call Scheduled for Tuesday, August 6, 2024, at 8:00 a.m. ET --
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2024-financial-results-on-august-6-2024-302211523.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will Karyopharm Therapeutics (KPTI) report its Q2 2024 financial results?
What time is Karyopharm's (KPTI) Q2 2024 earnings call scheduled for?
How can investors access Karyopharm's (KPTI) Q2 2024 earnings call?
Where can I find the slides for Karyopharm's (KPTI) Q2 2024 earnings presentation?
